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Effect of Early Everolimus-Facilitated Reduction of
Tacrolimus on Efficacy and Renal Function in De
Novo Liver Transplant Recipients: 24-Month
Results for the North American Subpopulation
William C. Chapman, MD,1 Robert S. Brown, Jr, MD,2 Kenneth D. Chavin, MD,3 Debra Sudan, MD,4
Baburao Koneru, MD,5 Guido Junge, MD,6 Gaohong Dong, PhD,7 Dharmesh Patel, MD,7 Lewis Teperman, MD,8
and John J. Fung, MD9
Background. A recent randomized phase III study of 719 de novo liver transplant recipients showed that early everolimus plus
reduced-dose tacrolimus (EVR + rTAC) led to significantly better kidney function than standard TAC (TAC-C), without compromising
efficacy. In that study, patients from North America (n = 211) had increased risk factors for posttransplant renal insufficiency at study
start, relative to patients from Europe and rest of world (eg, worse renal function, more diabetes, older age).Methods. A post hoc
analysis was performed to assess whether these regional disparities affected study outcomes in North American patients.Results.
In this subpopulation, estimated glomerular filtration rates at randomization were higher in TAC-C over EVR + rTAC (76.4 vs 69.3mL/
min per 1.73 m2). Mean changes in estimated glomerular filtration rate values (mL/min per 1.73 m2) favored EVR + rTAC over TAC-C
at months 12 (+3.7 vs −4.5; P = 0.032), 24 (+2.7 vs −6.6; P = 0.042), and 36 (+4.3 vs −8.1; P = 0.059). The composite efficacy
endpoint of treated biopsy-proven acute rejection, graft loss, or death was 10.9%, 14.1%, and 14.1% for EVR + rTAC and 13.1%,
17.2%, and 19.3% for TAC-C at months 12, 24, and 36, respectively. Conclusions. Although the North American cohort had
more comorbidities, results were consistent with the overall population for efficacy and renal function.
(Transplantation 2017;101: 341–349)
L iver transplantation has become a standard-of-care treat-ment modality for end-stage liver disease, with excellent
overall 5-year survival rates of around 70% or greater.1
However, one of the persistent challenges in the post-
transplant period has been management of renal complica-
tions associated with chronic immunosuppression therapy
required to prevent rejection of the transplanted graft. In
the United States, it is estimated that the 5-year incidence of
chronic renal failure after liver transplantation is 18.1%.2
Moreover, patients developing chronic renal failure have an
increased mortality risk that is estimated to be more than 4
times greater than those not developing chronic renal fail-
ure.2,3 The vast majority of patients who undergo liver trans-
plantation are currently placed on a calcineurin inhibitor
(CNI)-based immunosuppressive regimen, and this is a factor
associated with an increased risk of renal dysfunction.4
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Strategies to reduce CNI-related nephrotoxicity by early
CNI minimization/elimination are of particular interest in
the field of liver transplantation. Recently, in a 24-month in-
ternational, randomized, controlled study (H2304) in de novo
liver transplant recipients, it was shown that early everolimus
(EVR)-facilitated tacrolimus (TAC) dose reduction led to
significantly better kidney function versus standard TAC
(TAC-C) without compromising efficacy.5,6 The adjusted
change (via an analysis of covariance model) from ran-
domization in estimated glomerular filtration rate (eGFR),
based on the Modification of Diet in Renal Disease-4 var-
iables (MDRD4) formula,7 favored EVR + reduced TAC
(rTAC) over TAC-C by 8.5 mL/min per 1.73 m2
(P < 0.001) at month 12 and 6.7 mL/min per 1.73 m2
(P = 0.002) at month 24.5,6
There are notable differences in patients undergoing liver
transplantation in North America compared with other re-
gions in the world. For example, in the H2304 study, more
participants from North America compared with Europe
and rest of world (ROW) had hepatitis C virus (HCV) infec-
tion.8 This difference is not surprising because previous re-
ports have recognized that HCV infection is known to be
the most common cause of liver transplantation in the
United States.9 In addition, North American participants
from Study H2304 had lower eGFR values, and higher
model for end-stage liver disease (MELD) scores at time of
transplantation, than those from other regions.10 They also
had a higher incidence of diabetes and were older when
compared with individuals from Europe and ROW.8 These
factors are known to be associated with an increased risk
of chronic kidney disease or acute kidney injury.11,12
Regional variation in patient characteristics after liver trans-
plantation have also previously been reported in the litera-
ture.13 Because geographical disparities in risk factors for
posttransplant renal insufficiency could have an impact on
study outcomes, it is important to analyze data for specific
subpopulations to assess results in comparison to the overall
study population. Here we report a post hoc analysis of effi-
cacy, renal function, and adverse event (AE) results for the
H2304 North American subpopulation.
MATERIALS AND METHODS
Methods for Study H2304 were previously published in
detail5 and are briefly summarized here.
Study Design
This 24-month international, randomized, controlled
study in de novo liver transplant recipients compared 3
open-label treatments (Figure 1). An initial 30-day (±5 days)
posttransplantation run-in period with TAC (± mycopheno-
late mofetil [MMF]) was stratified by pretransplant HCV
status and eGFR (MDRD4). Participants were then random-
ized (1:1:1) into the treatment groups: EVR (trough concen-
tration [C0] 3-8 ng/mL) plus rTAC (C0 3-5 ng/mL)
(“EVR + rTAC”); EVR (C0 3–8 ng/mL to month 4, then
6–10 ng/mL) plus TAC (C0 3-5 ng/mL), with TAC with-
drawal by month 4 (TAC-WD); and standard TAC (C0
8-12 ng/mL to month 4, then 6-10 ng/mL) (“TAC-C”).
EVR was initiated at a dose of 1 mg twice daily, with dose
adjustment to achieve the target C0. All patients received
corticosteroids for a minimum of 180 days. Enrollment
in the TAC-WD arm was prematurely terminated, at the
recommendation of the independent data monitoring com-
mittee, due to higher rejection rates. Thereafter, eligible pa-
tients completing the run-in period were randomized 1:1 to
EVR + rTAC or TAC-C. Patients who had already been ran-
domized to the TAC-WD arm converted to local standard
treatment if ≤ 180 days after randomization, or either contin-
ued on their assigned treatment or converted to local standard
treatment if longer than 180 days after randomization.
Study Endpoints
The original protocol endpoints were noninferiority of
composite efficacy failure rate of death, graft loss, or loss
to follow-up (primary endpoint) and superior renal function
(coprimary endpoint), as assessed by eGFR (MDRD4), at
month 12. After implementation of the protocol amend-
ment to discontinue enrollment in the TAC-WD arm and
to implement the European Medicines Agency guideline
on clinical investigation of immunosuppressants for solid
organ transplantation,14 the primary and coprimary end-
points were separated into noninferior composite efficacy
failure rate of (a) treated biopsy-proven acute rejection
(tBPAR) (defined as an acute rejection with a locally con-
firmed rejection activity index of 3 or greater according to
Banff 1997 criteria15 treated with antirejection therapy),
(b) graft loss, or (c) death at month 12 (primary endpoint,
noninferiority margin = 12%), and noninferior renal function
as measured by change in eGFR (MDRD4) from randomiza-
tion tomonth 12 (key secondary endpoint, noninferioritymar-
gin = −6 mL/min per 1.73 m2).
Patients
Briefly, patients were adult (18-70 years of age) recipients
of a primary liver transplant from a deceased donor and
had received an immunosuppressive regimen containing cor-
ticosteroids and TAC 3 to 7 days after liver transplantation,
with 1 or more TAC C0 values of 8 ng/mL or greater in the
week before randomization. The eGFR (MDRD4) at ran-
domization was 30 mL/min per 1.73 m2 or greater. Patients
were excluded for the following reasons: recipients of multi-
ple solid-organ or islet-cell transplants, recipients of a liver
from a living donor or a split liver, history of malignancy of
any organ system within the past 5 years (except nonme-
tastatic basal or squamous cell carcinoma of the skin or hepa-
tocellular carcinoma), hepatocellular carcinoma not meeting
Milan criteria16,17 at the time of transplantation and any anti-
body induction therapy. AEs were summarized for the safety
population, which included all randomized patients who re-
ceived 1 dose or more of study medication. The majority of
discontinuations in the EVR + rTAC and TAC-C groups were
due to AEs; see Results section for further details.
Statistical Analysis
Efficacy and renal function (eGFR) analyses were per-
formed using the intent-to-treat population, which in-
cluded all randomized patients. eGFR values and changes
from randomization to each visit were compared between
the EVR + rTAC and TAC-C groups using the Wilcoxon
Rank-sum test. Data are primarily presented for the North
American subpopulation; results for the European and
ROW subpopulations are also described for context.
However, it is important to note that the study was not
designed to compare subpopulations from the various
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regions or to assess outcomes with respect to individual
risk factors. As this was an ad hoc analysis, no formal statis-
tical test was performed.
RESULTS
The following sections focus on the EVR + rTAC and
TAC-C treatment groups; results for the terminated TAC-WD
arm are shown in the tables and figures and briefly summa-
rized within the text.
Patients
Of the 719 randomized patients in the overall population,
211 were from North America (EVR + rTAC [n = 65],
TAC-WD [n = 68], and TAC-C [n = 78]); 419 were from
Europe (EVR + rTAC [n = 149], TAC-WD [n = 138], and
TAC-C [n = 132]); and 89 were from ROW (EVR + rTAC
[n = 31], TAC-WD [n = 25], and TAC-C [n = 33]). Patient dis-
position for the North American subpopulation is shown
in Figure 2.
Demographic and baseline characteristics for the overall
population and the North American subpopulation were
generally similar across the 3 treatment groups (Table 1). In
the North American subpopulation, mean and median eGFR
values at randomization were lower in the EVR + rTAC
group (69.3 and 66.1 mL/min per 1.73 m2, respectively) than
in the TAC-WD (82.2 and 76.1 mL/min per 1.73 m2) and
TAC-C (76.4 and 73.1 mL/min per 1.73 m2) treatment arms.
As mentioned previously, several other differences were ap-
parent between North American participants and those from
Europe andROW:mean age (54.8 vs 53.8 and 51.4 years, re-
spectively); diabetes (44% vs 29% and 34%), HCV infection
(49% vs 21% and 37%), mean eGFR values (76.1 vs 78.6 and
83.7 mL/min per 1.73 m2), body mass index (26.1 vs 24.4 and
25.2 kg/m2), and MELD scores (22.7 vs 17.6 and 18.5).
Immunosuppression
At randomization, mean trough levels of TAC were
10.3 ng/mL in the EVR + rTAC group and 9.8 ng/mL in the
TAC-C group (Table 2). At months 12 and 24, mean trough
levels of TAC were within the target ranges both in the
EVR + rTAC group (4.5 and 3.6 ng/mL, respectively; target,
3-5 ng/mL) and TAC-C group (7.7 and 6.7 ng/mL, respec-
tively; target, 6-10 ng/mL). At months 12 and 24, mean
trough levels of EVR were within the target range in the
EVR + rTAC group (5.8 and 6.1 ng/mL, respectively; target,
3-8 ng/mL). Results in Europe were similar to those in North
America; sample sizes in ROW were too limited for
meaningful comparison.
Renal Function
There was an imbalance in renal function at time of ran-
domization with lower values for North America compared
with Europe, as well as within the North American sub-
group, thus favoring the TAC-C group with a higher eGFR
at time of randomization. However, at most visits after ran-
domization in North America, treatment with EVR + rTAC
was associated with greater mean eGFR values (Figure 3)
and mean increases in eGFR values (Figure 4), versus
TAC-C treatment, with most mean increases being statisti-
cally significant (p < 0.05).
In North America, despite having lower eGFR at ran-
domization, mean eGFR values in the EVR + rTAC group
increased after randomization and were significantly
higher at month 3 versus the TAC-C group (Figure 3). At
month 12, mean eGFR values were 71.5 versus 70.5 mL/
min per 1.73 m2 (P = 0.549), respectively. Corresponding
results at month 24 were 68.4 versus 68.0 mL/min per
1.73 m2 (P = 0.747).
In contrast to mean eGFR values, mean changes in eGFR
values were observed from randomization to each visit in
the EVR + rTAC group, with statistically significant
(P < 0.05) differences favoring EVR + rTAC versus TAC-C
at all visits except week 5 (data not shown) and months 9
and 18 (Figure 4). At month 12, mean changes in eGFR
values were +3.7 versus −4.5 mL/min per 1.73 m2 (P = 0.032)
FIGURE 1. H2304 study design.
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for EVR + rTAC and TAC-C, respectively; corresponding me-
dian changes were −0.2 versus −6.1 mL/min per 1.73 m2. At
month 24, mean changes in eGFR values were +2.7 versus
−6.6 mL/min per 1.73m2 (P = 0.042), respectively; correspond-
ing median changes were +1.4 and −9.4 mL/min per 1.73 m2.
The terminated TAC-WD arm had the highest mean eGFR
values throughout the study (82.2, 81.7, and 75.0 mL/min
per 1.73 m2 at randomization, month 12, and month 24, re-
spectively). Mean reductions in eGFR values were observed
from randomization to months 12 and 24 (−3.0 and
−10.0 mL/min per 1.73 m2, respectively); corresponding me-
dian changes were −0.2 and −0.6 mL/min per 1.73 m2.
Alternative measures (MDRD6, CKD-EPI, serum creati-
nine, Nankivell, Cockcroft-Gault, and cystatin C) to calcu-
late eGFR were also assessed. The results were similar to
those reported with MDRD4, that is, significantly better
mean eGFR changes versus TAC-C in almost all cases (data
not shown).
Efficacy
Efficacy results are summarized in Table 3 and Figure 5. In
North America, the Kaplan-Meier incidence rate of the pri-
mary composite efficacy endpoint of tBPAR, graft loss, or
death for EVR + rTAC at month 12 and month 24 were
10.9% and 14.1%, respectively, and for TAC-C were
13.1% and 17.2% (Table 3 and Figure 5A).
tBPAR occurred in 4 (6.2%) of 65 patients in the
EVR + rTAC group and 9 (11.5%) of 78 patients in the
TAC-C group at month 12. At month 24, the Kaplan-Meier
incidence rate of tBPAR was 8.1% for EVR + rTAC and
13.2% for TAC-C (Table 3 and Figure 5B).
The terminated TAC-WD arm was associated with the
highest event rate of the primary composite efficacy end-
point, primarily driven by a higher tBPAR rate within
3 months of withdrawal of TAC. The primary composite ef-
ficacy endpoint, for example, had Kaplan-Meier incidence
rates of 24.6%and 25.9%atmonths 12 and 24, respectively.
InEuropeandROW,comparabilitybetweentheEVR+rTAC
and TAC-C arms was also shown for the above endpoints.
Adverse Events
The most common AEs reported in the North American
subpopulation are shown in Table 4. Throughout the study,
themajority of themost commonAEswere reported at a sim-
ilar incidence in the EVR + rTAC and TAC-C groups. Inci-
dence of specific AEs of interest in the EVR + rTAC and
TAC-C groups were as follows: hypertension (26.2% vs
14.1%, respectively), leukopenia (20.0% vs 7.7%), abdomi-
nal pain (12.3% vs 20.5%), nausea (15.4% vs 21.8%),
vomiting (9.2% vs 15.4%), insomnia (6.2% vs 17.9%),
and hyperkalemia (7.7% vs 20.5%). The vast majority of
AEs occurred during the initial year of therapy (Table 4).
AEs affecting the cardiovascular systemwere reported in 11
(16.9%) patients in the EVR + rTAC group and 14 (17.9%)
patients in the TAC-C group. AEs reported by more than
1 patient in either group (EVR+ rTAC vs TAC-C, respectively)
included: angina pectoris (2 [3.1%], 4 [5.1%]), tachycardia
(3 [4.6%], 3 [3.8%]), atrial fibrillation (2 [3.1%], 1 [1.3%]),
coronary artery disease (2 [3.1%], 1 [1.3%]), myocardial is-
chemia (0, 3 [3.8%]), acute myocardial infarction (0, 2
[2.6%]), and cardiomegaly (2 [3.1%], 0). Diabetes mellitus
was reportedas anAE in5 (7.7%)patients in theEVR+rTAC
FIGURE 2. Patient disposition for North American subpopulation.
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group and 4 (5.1%) patients in the TAC-C group. AEs of
lipid metabolism in the EVR + rTAC and TAC-C groups, re-
spectively, included hypercholesterolemia (5 [7.7%], 2
[2.6%]), hyperlipidemia (5 [7.7%], 2 [2.6%]), and hypertri-
glyceridemia (5 [7.7%], 1 [1.3%]).
Wound infections were infrequent during the study, with
only 2 (3.1%) AE reports in the EVR + rTAC group com-
pared with 0 in the other treatment groups. Proteinuria was
also uncommon: 0 with EVR + rTAC treatment and 1
(1.3%) with TAC-C treatment. A single case of stomatitis
was reported in the EVR + rTAC group. AEs of infections/
infestations occurred at a similar rate between treatments,
with the most common being HCV (23.1% vs 20.5% in
the EVR + rTAC vs TAC-C groups, respectively).
Throughout the study, AEs resulted in the discontinuation
of study medication for 20 (30.8%) patients in the
EVR + rTAC group and 14 (17.9%) patients in the TAC-C
group (Figure 2). The only AEs that led to the discontinua-
tion of more than 1 patient in these treatment groups were
hepatitis C infection/acute hepatitis (n = 2) in the EVR+ rTAC
group and renal failure (n = 3), hepatitis C infection (n = 2),
and increased blood creatinine (n = 2) in the TAC-C group.
Most discontinuations resulting from AEs occurred within
6 months of randomization.
TABLE 2.
Tacrolimus trough levels at randomization, month 12 and month 24 in the overall H2304 population and the North
American subpopulation
North American subpopulation Total H2304 population
Visit Statistic EVR + rTAC (n = 65) TAC-C (n = 78) EVR + rTAC (N = 245) TAC-C (N = 243)
Randomization/week 4 n 57 73 205 211
Mean (SD) 10.3 (4.5) 9.8 (3.3) 10.5 (4.2) 10.0 (3.1)
Month 12 n 32 50 135 148
Mean (SD) 4.5 (1.8) 7.7 (2.8) 4.9 (2.1) 7.7 (2.8)
Month 24 n 22 41 109 128
Mean (SD) 3.6 (1.5) 6.7 (2.6) 4.0 (1.7) 7.0 (2.5)
TABLE 1.
Demographic andbaseline characteristics of intent-to-treat in the overall H2304population and theNorthAmerican subpopulation
North American subpopulation Total H2304 population
Characteristics EVR + rTAC (n = 65) TAC-WD (n = 68) TAC-C (n = 78) EVR + rTAC (N = 245) TAC-WD (N = 231) TAC-C (N = 243)
Age: mean ± SD, y 54.2 ± 8.3 55.5 ± 8.5 54.7 ± 7.3 53.6 ± 9.2 53.2 ± 10.8 54.5 ± 8.7
Sex, n (%)
Male 47 (72.3) 51 (75.0) 55 (70.5) 180 (73.5) 164 (71.0) 179 (73.7)
Female 18 (27.7) 17 (25.0) 23 (29.5) 65 (26.5) 67 (29.0) 64 (26.3)
Race, n (%)
White 56 (86.2) 54 (79.4) 64 (82.1) 211 (86.1) 196 (84.8) 195 (80.2)
Black 4 (6.2) 5 (7.4) 8 (10.3) 4 (1.6) 6 (2.6) 9 (3.7)
Other 5 (7.7) 9 (13.2) 6 (7.7) 30 (12.2) 29 (12.6) 39 (16.0)
BMI: mean ± SD, kg/m2 26.5 ± 4.5 26.6 ± 4.5 25.4 ± 4.8 25.2 ± 4.2 25.3 ± 4.3 24.5 ± 4.2
HCV positive status, n (%) 31 (47.7) 32 (47.1) 41 (52.6) 79 (32.2) 72 (31.2) 76 (31.3)
eGFR (MDRD4) at randomization, mL/min per 1.73 m2
Mean ± SD 69.3 ± 26.1 82.2 ± 39.9 76.4 ± 24.4 81.3 ± 33.3 82.9 ± 37.2 78.8 ± 27.7
Median 66.1 76.1 73.1 75.7 75.7 77.4
Diabetic at randomization, n (%) 28 (43.1) 30 (44.1) 39 (50.0) 87 (35.5) 79 (34.2) 97 (39.9)
Primary disease leading to liver transplantation, n (%)
Hepatitis C 29 (44.6) 27 (39.7) 36 (46.2) 61 (24.9) 55 (23.8) 56 (23.0)
Alcoholic cirrhosis 13 (20.0) 12 (17.6) 4 (5.1) 70 (28.6) 49 (21.2) 51 (21.0)
Hepatocellular carcinoma 4 (6.2) 8 (11.8) 6 (7.7) 44 (18.0) 32 (13.9) 36 (14.8)
Cryptogenic cirrhosis 5 (7.7) 2 (2.9) 7 (9.0) 7 (2.9) 11 (4.8) 18 (7.4)
Primary biliary cirrhosis 5 (7.7) 3 (4.4) 3 (3.8) 8 (3.3) 11 (4.8) 8 (3.3)
Sclerosing cholangitis 0 5 (7.4) 5 (6.4) 8 (3.3) 20 (8.7) 12 (4.9)
Hepatitis B 2 (3.1) 3 (4.4) 2 (2.6) 16 (6.5) 17 (7.4) 15 (6.2)
Autoimmune liver hepatitis 1 (1.5) 0 2 (2.6) 4 (1.6) 7 (3.0) 6 (2.5)
Other 6 (9.2) 8 (11.8) 13 (16.7) 27 (11.0) 29 (12.6) 41 (16.9)
MELD score, mean ± SD 22.8 ± 10.8 22.6 ± 6.4 22.6 ± 6.2 19.2 ± 9.0 19.6 ± 7.5 19.0 ± 7.6
Donor age, mean ± SD 42.2 ± 16.2 42.3 ± 17.0 40.8 ± 15.2 48.8 ± 18.2 50.0 ± 18.2 48.7 ± 17.4
Cold ischemia time: mean ± SD, h 7.4 ± 4.31 6.4 ± 2.32 6.5 ± 2.23 7.9 ± 4.4 7.1 ± 2.8 7.6 ± 5.2
a n = 63, b n = 67, c n = 77.
BMI, body mass index.
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In the terminated TAC-WD arm, AEs were reported in
91.2% of North American patients over the course of the
study, the most common of which were diarrhea (25.0%),
abnormal liver function tests (23.5%), abdominal pain
(22.1%), peripheral edema (19.1%), and pyrexia (19.1%).
In Europe and ROW, overall AE and discontinuation
rates were similar to those in North America. The differ-
ences in individual AE rates mentioned above were not seen
in Europe, with the exception of a higher incidence of leuko-
penia in the EVR + rTAC group compared with the TAC-C
group (8.1% vs 1.5%).
3-Year Results
After the 24-month core study, patients who completed
24-month treatment were offered enrollment into the ex-
tension study. After informed consent, in the North
American subpopulation, 22 patients in the EVR + rTAC
group, 15 patients in the TAC-WD group, and 42 patients
in the TAC-C group were followed up until month 36;
14 patients in the EVR + rTAC group and 14 patients in
the TAC-WD group were followed up to month 48. The
mean change in eGFR from randomization to month 36
was +4.3 versus −8.1 mL/min per 1.73 m2 (P = 0.059) in
the EVR + rTAC and TAC-C groups, respectively. Over
the same time period, the primary composite efficacy fail-
ure occurred in 14.1% of patients in the EVR + rTAC
group and 19.3% of patients in the TAC-C group
(P = 0.42). Between months 24 and 36, AEs were reported
in 90.9% and 78.6% of patients and SAEs were reported
in 31.8% and 28.6% of patients, respectively.
DISCUSSION
This report presents important subset analysis data on pa-
tients from North America participating in the H2304 ran-
domized trial investigating the role and benefit of EVR for
TAC dose reduction compared with standard-dose TAC
immunosuppression. The use of EVR with TAC allowed
for substantial and safe TAC reduction with resulting com-
parable efficacy and improved eGFR at month 12
FIGURE 3. Mean eGFR values (MDRD4 formula) over time in the intent-to-treat North American subpopulation.
FIGURE 4. Mean change in eGFR values (MDRD4 formula) from randomization over time in the intent-to-treat North American subpopulation.
346 Transplantation ■ February 2017 ■ Volume 101 ■ Number 2 www.transplantjournal.com
compared with patients treated in the standard TAC con-
trol arm. Importantly, the improvement in eGFR was pre-
served at month 24 and month 36 (albeit the sample size
was limited at this latter time point) with EVR + rTAC, in
comparison to TAC-C. Thus, North American patients ex-
posed to EVR + rTAC, despite having worse renal function
and higher MELD scores at study start, had findings that
were consistent with those of European patients and the pre-
viously reported overall population.5,6
North American patients enrolled in the current study had
slightly worse renal function for those randomized to
EVR + rTAC compared with the control TAC arm (eGFR:
FIGURE 5. Kaplan-Meier plot of the proportion of patients free from (a) the primary composite efficacy endpoint of tBPAR, graft loss, or death
and (b) tBPAR in the intent-to-treat North American subpopulation.
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69.3 vs 76.4 mL/min per 1.73 m2). These differences can be
attributed to this study being a post hoc analysis on a sub-
group of the H2304 study, and so the randomization of sub-
jects was not controlled for the North American cohort. Our
therapeutic drug monitoring data showed that at month 24
mean trough levels of TACwere 3.6 ng/mL in the EVR+ rTAC
armversus 6.7 ng/mL in the TAC-C arm (slightly lower than in
the overall population: ~4.0 and ~7.0 ng/mL, respectively).6
This finding indicates that use of EVR was successful in de-
creasing CNI exposure. Although the TAC-WD arm was pre-
maturely terminated in this study, it should be noted that
PROTECT, a separate long-term study assessing the effect of
EVR treatment and TAC elimination on renal outcomes in
de novo liver transplant recipients, was successfully continued
for up to 60 months, and reported significantly better renal
function and comparable patient and graft outcomes vs
CNI-based immunosuppression.18
An important goal of the H2304 study was to establish
that EVR for CNI exposure reduction was safe to use after
liver transplantation. In this trial, the primary composite
efficacy failure rate of tBPAR, graft loss, or death was
noninferior with EVR + rTAC versus TAC-C at month 12
(6.7% vs 9.7%) and month 24 (10.3% vs 12.5%).5,6 The
United States Prescribing Information (USPI) states a slightly
different composite efficacy failure endpoint in its evaluation
of this study (ie, tBPAR, graft loss, death, or loss to follow-
up), which also showed noninferiority between the 2 treat-
ment groups (9.0% EVR + rTAC vs 13.6% TAC-C at month
12).19 In the USPI analysis of the composite efficacy failure
endpoint of tBPAR, graft loss, death, or loss to follow-up,19
deaths that occurred after study discontinuation or study
drug discontinuation were also included in the data analysis.
Although this approach was not taken in our intent-to-treat
analysis, there were noNorthAmerican patientswho died af-
ter study or study drug discontinuation and, thus, our results
for this endpoint were identical to those using the USPI defi-
nition. A previous study found that the incidence of BPAR
was significantly greater with MMF and sirolimus (12.2%)
versus MMF and TAC (4.1%) at 12 months posttransplant,
and that sirolimus was poorly tolerated.20 In the current
TABLE 4.
Patients reporting most common (≥10%) adverse events in safety North American subpopulation
Adverse events, n (%)
Month 12 Month 24
EVR + rTAC (n = 65) TAC-WD (n = 68) TAC-C (n = 78) EVR + rTAC (n = 65) TAC-WD (n = 68) TAC-C (n = 78)
Any adverse event 63 (96.9) 63 (92.6) 74 (94.9) 64 (98.5) 62 (91.2) 77 (98.7)
Diarrhea 11 (16.9) 16 (23.5) 17 (21.8) 14 (21.5) 17 (25.0) 20 (25.6)
Headache 14 (21.5) 9 (13.2) 18 (23.1) 16 (24.6) 10 (14.7) 21 (26.9)
Hepatitis C 13 (20.0) 11 (16.2) 13 (16.7) 15 (23.1) 12 (17.6) 16 (20.5)
Fatigue 12 (18.5) 8 (11.8) 16 (20.5) 15 (23.1) 10 (14.7) 16 (20.5)
Abdominal pain 8 (12.3) 11 (16.2) 12 (15.4) 8 (12.3) 15 (22.1) 16 (20.5)
Hypertension 14 (21.5) 9 (13.2) 10 (12.8) 17 (26.2) 10 (14.7) 11 (14.1)
Abnormal liver function test 9 (13.8) 15 (22.1) 11 (14.1) 10 (15.4) 16 (23.5) 11 (14.1)
Nausea 9 (13.8) 10 (14.7) 15 (19.2) 10 (15.4) 10 (14.7) 17 (21.8)
Pyrexia 5 (7.7) 11 (16.2) 11 (14.1) 11 (16.9) 13 (19.1) 12 (15.4)
Increased hepatic enzyme 9 (13.8) 11 (16.2) 9 (11.5) 10 (15.4) 12 (17.6) 12 (15.4)
Peripheral edema 10 (15.4) 12 (17.6) 7 (9.0) 11 (16.9) 13 (19.1) 10 (12.8)
Tremor 9 (13.8) 5 (7.4) 12 (15.4) 10 (15.4) 5 (7.4) 15 (19.2)
Vomiting 4 (6.2) 6 (8.8) 11 (14.1) 6 (9.2) 7 (10.3) 12 (15.4)
Insomnia 4 (6.2) 5 (7.4) 9 (11.5) 4 (6.2) 6 (8.8) 14 (17.9)
Leukopenia 13 (20.0) 4 (5.9) 6 (7.7) 13 (20.0) 4 (5.9) 6 (7.7)
Back pain 5 (7.7) 5 (7.4) 11 (14.1) 7 (10.8) 4 (5.9) 11 (14.1)
Hyperkalemia 5 (7.7) 1 (1.5) 16 (20.5) 5 (7.7) 1 (1.5) 16 (20.5)
Nasopharyngitis 8 (12.3) 4 (5.9) 6 (7.7) 9 (13.8) 5 (7.4) 8 (10.3)
Adverse events shown are those reported in ≥ 10% of patients at either month 12 or month 24. Adverse events are sorted by overall frequency of occurrence at month 24.
TABLE 3.
Summary of efficacy results at months 12 and 24 in the intent-to-treat North American subpopulation
Efficacy parameter, n (%)
Month 12 Month 24a
EVR + rTAC
(n = 65)
TAC-WD
(n = 68)
TAC-C
(n = 78)
Risk Difference:
EVR + rTAC vs TAC-C
(95% CI)
EVR + rTAC
(n = 65)
TAC-WD
(n = 68)
TAC-C
(n = 78)
Risk Difference of
EVR + rTAC vs TAC-C
(95% CI)
tBPAR, graft loss, or death (primary endpoint) 7 (10.9)a 14 (24.6)a 10 (13.1)a −2.1 (−12.9 to 8.6) 9 (14.1) 16 (25.9) 13 (17.2) −3.0 (−15.1 to 9.0)
tBPAR 4 (6.2) 14 (20.6) 9 (11.5) −5.4 (−14.6 to 3.8) 5 (8.1) 14 (22.5) 10 (13.2) −5.1 (−15.4 to 5.1)
Graft loss or death 4 (6.3)a 0 (0.0)a 1 (1.3)a 4.9 (−1.5 to 11.4) 5 (7.9) 3 (5.1) 4 (5.4) 2.5 (−5.9 to 10.9)
Graft loss, death, or loss to follow-up 5 (7.7) 7 (10.3) 6 (7.7) 0.0 (−8.8 to 8.8) 11 (16.9) 12 (17.7) 8 (10.3) 6.7 (−4.7 to 18.0)
tBPAR, graft loss, death, or loss to follow-up 8 (12.3) 21 (30.9) 14 (17.9) −5.6 (−17.3 to 6.0) 15 (23.1) 24 (35.3) 17 (21.8) 1.3 (−12.5 to 15.0)
a Kaplan-Meier incidence rate is shown.
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analysis, EVR was well tolerated and tBPAR incidence at
month 12 was lower with EVR + rTAC (6.2%) than with
TAC-C (11.5%).
Important demographic differences were identified in
North American patients when compared with European
and ROW patients. As mentioned previously, patients were
older, had higher body mass index and higher MELD scores
at transplant, and had higher rates of diabetes and HCV in-
fection associated with their chronic liver disease. Given that
theNorth American patients had higher rates of these comor-
bidities, it is reassuring that the use of EVR + rTAC allowed
for improved renal preservation in this cohort comparedwith
the TAC-C arm of the study.
There are limitations to the current study. First, the H2304
study was developed as an international trial with no a priori
plan to compare results across regions as well as between
treatment arms within a given region. Second, the small sam-
ple sizes of subpopulations limit the ability to demonstrate
significant differences in some of the outcomes; hence, the
data are presented for the North American population as a
whole. However, this study does demonstrate excellent im-
munosuppression and renal function outcomes for North
American patients, despite the differences in study cohorts
that existed at baseline. A follow-up study on a larger cohort
ofNorthAmerican patients iswarranted.Third, EVR+ rTAC
is the only approved regimen to lower TAC exposure in liver
transplant recipients. Other immunosuppressive regimens
are sometimes used to decrease CNI exposure in this popula-
tion, including TAC + mycophenolic acid; however, the regi-
men of TAC + mycophenolic acid is not approved in liver
transplantation and so was not investigated as part of the
current study. The use of EVRwith mycophenolic acid deriv-
atives without CNIsmay be another renal-protective strategy
used in liver transplant recipients.21 Fourth, there were high
rates of discontinuation in both the EVR + rTAC and
TAC-C groups (49.2% vs 32.1%). The higher discontinua-
tion rate in the EVR + rTAC arm might be attributable to
the fact that this is the experimental arm and so clinicians
would have been less familiar with this treatment in compar-
ison to the standard treatment.
CONCLUSIONS
In summary, this report demonstrates thatNorth American
patients enrolled in the H2304 international trial investigat-
ing use of EVR to facilitate rTAC for immunosuppression af-
ter liver transplant had improved renal function at months
12 and 24 after study enrollment. The North American co-
hort had higher MELD scores at transplant and higher co-
morbidities with increased rates of diabetes, HCV, obesity,
and MELD score at time of transplant compared with pa-
tients enrolled in Europe and ROW. In addition, patients
randomized to the EVR + rTAC arm of the trial in North
America had worse renal function at baseline compared
with patients in the TAC-C arm of the trial. Nevertheless,
North American patients randomized to EVR + rTACmain-
tained significantly better renal function (ie, improved mean
change from baseline in eGFR) at month 12 and 24 com-
pared with patients in the standard TAC dosing arm of the
trial. Improvement in renal function was maintained at
month 36. We believe this treatment strategy may allow
for excellent immunosuppression with reduced risks of renal
insufficiency after liver transplantation.
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